The March 2009 issue of Drug and Therapeutics Bulletin (DTB) contains an editorial and three articles. The editorial discusses private ‘high street mole clinics’, a development that has been questioned in a recent UK All Party Parliamentary report. The issue also includes a review of the management of acute sinusitis, a review of a new testosterone patch for sexual dysfunction in women, and the second in a series of explanatory articles about understanding statistical terms.
New imaging technologies for assessing suspect pigmented lesions to help the early diagnosis of skin cancer have, in part, led to privately run ‘high street mole clinics’. In the first podcast by the DTB (Drug and Therapeutics Bulletin), consultant dermatologist Julia Schofield and DTB editor Ike Iheanacho discuss the place of these clinics.
http://podcasts.bmj.com/dtb/
Merck is to buy rival Schering-Plough in a $41.1bn (£29.4bn) deal, creating one of the world’s biggest pharmaceutical companies. The merger unites the makers of cholesterol drugs Zetia and Vytorin at a time of falling sales. Other drug companies that saw falls included Johnson & Johnson and Pfizer, down 2.9% and 0.8% respectively. The deal follows Pfizer’s $68bn takeover of Wyeth, unveiled in January.
BBC 9/3/9 http://news.bbc.co.uk/1/hi/business/7932264.stm
Powered by WordPress